- Home
- MRKR vs CRIS Comparison
MRKR vs CRIS Comparison
Compare MRKR & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRKR
- CRIS
- Stock Information
- Founded
- MRKR N/A
- CRIS 2000
- Country
- MRKR United States
- CRIS United States
- Employees
- MRKR N/A
- CRIS N/A
- Industry
- MRKR Biotechnology: Pharmaceutical Preparations
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MRKR Health Care
- CRIS Health Care
- Exchange
- MRKR Nasdaq
- CRIS Nasdaq
- Market Cap
- MRKR 19.1M
- CRIS 21.3M
- IPO Year
- MRKR N/A
- CRIS 2000
- Fundamental
- Price
- MRKR $1.71
- CRIS $1.81
- Analyst Decision
- MRKR Strong Buy
- CRIS Strong Buy
- Analyst Count
- MRKR 3
- CRIS 2
- Target Price
- MRKR $13.17
- CRIS $16.50
- AVG Volume (30 Days)
- MRKR 102.6K
- CRIS 163.8K
- Earning Date
- MRKR 08-13-2025
- CRIS 07-31-2025
- Dividend Yield
- MRKR N/A
- CRIS N/A
- EPS Growth
- MRKR N/A
- CRIS N/A
- EPS
- MRKR N/A
- CRIS N/A
- Revenue
- MRKR $5,696,123.00
- CRIS $11,202,000.00
- Revenue This Year
- MRKR N/A
- CRIS N/A
- Revenue Next Year
- MRKR $11.28
- CRIS $10.67
- P/E Ratio
- MRKR N/A
- CRIS N/A
- Revenue Growth
- MRKR 71.53
- CRIS 14.17
- 52 Week Low
- MRKR $0.95
- CRIS $1.02
- 52 Week High
- MRKR $5.99
- CRIS $8.29
- Technical
- Relative Strength Index (RSI)
- MRKR 60.22
- CRIS 43.58
- Support Level
- MRKR $1.56
- CRIS $1.50
- Resistance Level
- MRKR $1.93
- CRIS $1.98
- Average True Range (ATR)
- MRKR 0.10
- CRIS 0.19
- MACD
- MRKR 0.02
- CRIS -0.05
- Stochastic Oscillator
- MRKR 57.69
- CRIS 43.88
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.